Zoetis (ZTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, with virtual participation and voting options for shareholders as of March 27, 2026.
2025 revenue reached $9.5B, with 6% organic operational revenue growth and 7% organic operational adjusted net income growth.
Strategic focus on innovation, digital transformation, sustainability, and global expansion, with investments in R&D and operational resilience.
Board and management emphasize strong governance, risk oversight, and shareholder engagement.
Voting matters and shareholder proposals
Election of twelve directors for one-year terms.
Advisory vote to approve executive compensation (Say on Pay).
Advisory vote on the frequency of future Say on Pay votes, with Board recommending annual votes.
Ratification of KPMG LLP as independent auditor for 2026.
Shareholder proposal to permit action by written consent, which the Board recommends voting against.
Board of directors and corporate governance
Board consists of twelve directors post-2026 meeting, with a majority independent and a mix of tenures and backgrounds.
Board refreshment ongoing, with four new independent directors added in the last four years.
Annual board and committee self-evaluations, mandatory retirement at age 75, and robust director nomination process.
Proxy access and special meeting rights for shareholders owning 25% of shares for at least one year.
Latest events from Zoetis
- Driving animal health innovation and growth with a diverse portfolio and global scale.ZTS
Corporate presentation8 Apr 2026 - Key votes include director elections, say-on-pay, auditor ratification, and written consent rights.ZTS
Proxy filing8 Apr 2026 - Growth in 2026 will be led by parasiticides, innovation in long-acting therapies, and expanding franchises.ZTS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Triple combination parasiticides and livestock drive growth amid resilient global demand.ZTS
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong product innovation and market expansion drive growth amid resilient pet health spending.ZTS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2026 guidance reflects resilience, innovation, and a synchronized global reporting calendar.ZTS
BofA Securities Animal Health Summit26 Feb 2026 - 2025 saw 6% organic growth, robust franchises, and strong 2026 guidance for further gains.ZTS
Q4 202512 Feb 2026 - Strong Q1 growth, robust innovation pipeline, and expanding alternative channels drive outlook.ZTS
Stifel Jaws & Paws Conference 20253 Feb 2026 - Q2 revenue up 11% operationally, adjusted net income up 18%, and $6B buyback approved.ZTS
Q2 20242 Feb 2026